109 related articles for article (PubMed ID: 20174763)
1. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis.
Basili S; Raparelli V; Vestri A; Di Tanna GL; Violi F
Thromb Haemost; 2010 Apr; 103(4):766-73. PubMed ID: 20174763
[TBL] [Abstract][Full Text] [Related]
2. Anti-platelet therapy: is it all over in peripheral artery disease?
Jaipersad AS; Silverman SH; Lip GY
Thromb Haemost; 2010 Apr; 103(4):689-91. PubMed ID: 20174749
[No Abstract] [Full Text] [Related]
3. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
; Leizorovicz A; Becker F
Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
[TBL] [Abstract][Full Text] [Related]
4. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
[TBL] [Abstract][Full Text] [Related]
5. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials.
WAVE Investigators
Am Heart J; 2006 Jan; 151(1):1-9. PubMed ID: 16368284
[TBL] [Abstract][Full Text] [Related]
6. Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Violi F; Balsano F
Clin Trials Metaanal; 1994 Apr; 29(1):81-7. PubMed ID: 10150187
[TBL] [Abstract][Full Text] [Related]
7. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Thijs V; Lemmens R; Fieuws S
Eur Heart J; 2008 May; 29(9):1086-92. PubMed ID: 18349026
[TBL] [Abstract][Full Text] [Related]
8. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet agents for intermittent claudication.
Wong PF; Chong LY; Mikhailidis DP; Robless P; Stansby G
Cochrane Database Syst Rev; 2011 Nov; (11):CD001272. PubMed ID: 22071801
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
Berger JS; Brown DL; Becker RC
Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
[TBL] [Abstract][Full Text] [Related]
11. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
12. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
Lièvre M; Cucherat M
Fundam Clin Pharmacol; 2010 Jun; 24(3):385-91. PubMed ID: 19678849
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis.
Girolami B; Bernardi E; Prins MH; ten Cate JW; Prandoni P; Hettiarachchi R; Marras E; Stefani PM; Girolami A; Büller HR
Thromb Haemost; 1999 May; 81(5):715-22. PubMed ID: 10365743
[TBL] [Abstract][Full Text] [Related]
14. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Poredos P; Jezovnik MK
Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
[TBL] [Abstract][Full Text] [Related]
16. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
18. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
19. [The future prospects of antithrombotic therapy in peripheral vasculopathy].
Violi F; Loffredo L; Annessi M
Ann Ital Med Int; 1999; 14(3):185-91. PubMed ID: 10566184
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
